nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—NPY1R—nerve—hypothyroidism	0.0332	0.138	CbGeAlD
Duloxetine—Pharyngeal oedema—Liotrix—hypothyroidism	0.0188	0.0307	CcSEcCtD
Duloxetine—HTR2A—cerebellar cortex—hypothyroidism	0.0185	0.0767	CbGeAlD
Duloxetine—Muscle twitching—Liothyronine—hypothyroidism	0.0151	0.0247	CcSEcCtD
Duloxetine—SLC6A3—nerve—hypothyroidism	0.014	0.058	CbGeAlD
Duloxetine—Gastric irritation—Liotrix—hypothyroidism	0.0138	0.0226	CcSEcCtD
Duloxetine—NPY1R—adrenal cortex—hypothyroidism	0.0128	0.0529	CbGeAlD
Duloxetine—CYP1A2—urine—hypothyroidism	0.0126	0.0521	CbGeAlD
Duloxetine—Phlebitis—Liothyronine—hypothyroidism	0.0125	0.0205	CcSEcCtD
Duloxetine—Cardiac failure congestive—Liothyronine—hypothyroidism	0.0119	0.0194	CcSEcCtD
Duloxetine—SLC6A2—nerve—hypothyroidism	0.0113	0.0468	CbGeAlD
Duloxetine—Throat tightness—Liotrix—hypothyroidism	0.0109	0.0179	CcSEcCtD
Duloxetine—NPY1R—gonad—hypothyroidism	0.0106	0.0438	CbGeAlD
Duloxetine—NPY1R—pituitary gland—hypothyroidism	0.0103	0.0427	CbGeAlD
Duloxetine—Epigastric discomfort—Liotrix—hypothyroidism	0.0102	0.0167	CcSEcCtD
Duloxetine—HTR2A—urine—hypothyroidism	0.00983	0.0407	CbGeAlD
Duloxetine—NPY1R—adrenal gland—hypothyroidism	0.00921	0.0382	CbGeAlD
Duloxetine—NPY1R—blood—hypothyroidism	0.00921	0.0382	CbGeAlD
Duloxetine—CYP2D6—urine—hypothyroidism	0.00895	0.0371	CbGeAlD
Duloxetine—NPY1R—thyroid gland—hypothyroidism	0.00889	0.0368	CbGeAlD
Duloxetine—SLC6A4—Monoamine Transport—SLC5A7—hypothyroidism	0.00826	0.0562	CbGpPWpGaD
Duloxetine—Acute coronary syndrome—Liothyronine—hypothyroidism	0.00819	0.0134	CcSEcCtD
Duloxetine—Myocardial infarction—Liothyronine—hypothyroidism	0.00814	0.0133	CcSEcCtD
Duloxetine—NPY1R—testis—hypothyroidism	0.00762	0.0316	CbGeAlD
Duloxetine—SLC6A2—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.00747	0.0509	CbGpPWpGaD
Duloxetine—NPY1R—liver—hypothyroidism	0.0072	0.0299	CbGeAlD
Duloxetine—SLC6A2—Monoamine Transport—SLC5A7—hypothyroidism	0.0071	0.0483	CbGpPWpGaD
Duloxetine—Feeling hot—Liotrix—hypothyroidism	0.00684	0.0112	CcSEcCtD
Duloxetine—HTR2A—nerve—hypothyroidism	0.00678	0.0281	CbGeAlD
Duloxetine—Arrhythmia—Liothyronine—hypothyroidism	0.00666	0.0109	CcSEcCtD
Duloxetine—SLC6A3—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.00662	0.0451	CbGpPWpGaD
Duloxetine—SLC6A3—Monoamine Transport—SLC5A7—hypothyroidism	0.00629	0.0428	CbGpPWpGaD
Duloxetine—Disorientation—Dextrothyroxine—hypothyroidism	0.00592	0.00967	CcSEcCtD
Duloxetine—Disorientation—Levothyroxine—hypothyroidism	0.00592	0.00967	CcSEcCtD
Duloxetine—Cardiac failure congestive—Dextrothyroxine—hypothyroidism	0.00584	0.00954	CcSEcCtD
Duloxetine—Cardiac failure congestive—Levothyroxine—hypothyroidism	0.00584	0.00954	CcSEcCtD
Duloxetine—Oliguria—Liotrix—hypothyroidism	0.00582	0.00951	CcSEcCtD
Duloxetine—NPY1R—Peptide GPCRs—TSHR—hypothyroidism	0.00575	0.0391	CbGpPWpGaD
Duloxetine—Increased appetite—Levothyroxine—hypothyroidism	0.00564	0.00921	CcSEcCtD
Duloxetine—Increased appetite—Dextrothyroxine—hypothyroidism	0.00564	0.00921	CcSEcCtD
Duloxetine—Hypertension—Liothyronine—hypothyroidism	0.00561	0.00916	CcSEcCtD
Duloxetine—Muscle twitching—Liotrix—hypothyroidism	0.00546	0.00893	CcSEcCtD
Duloxetine—Hypoglycaemia—Dextrothyroxine—hypothyroidism	0.00542	0.00887	CcSEcCtD
Duloxetine—Hypoglycaemia—Levothyroxine—hypothyroidism	0.00542	0.00887	CcSEcCtD
Duloxetine—Cardiac failure—Dextrothyroxine—hypothyroidism	0.00542	0.00887	CcSEcCtD
Duloxetine—Cardiac failure—Levothyroxine—hypothyroidism	0.00542	0.00887	CcSEcCtD
Duloxetine—Affect lability—Levothyroxine—hypothyroidism	0.00521	0.00852	CcSEcCtD
Duloxetine—Affect lability—Dextrothyroxine—hypothyroidism	0.00521	0.00852	CcSEcCtD
Duloxetine—Tachycardia—Liothyronine—hypothyroidism	0.00517	0.00845	CcSEcCtD
Duloxetine—Irritability—Levothyroxine—hypothyroidism	0.00505	0.00826	CcSEcCtD
Duloxetine—Irritability—Dextrothyroxine—hypothyroidism	0.00505	0.00826	CcSEcCtD
Duloxetine—Mood swings—Dextrothyroxine—hypothyroidism	0.00502	0.0082	CcSEcCtD
Duloxetine—Mood swings—Levothyroxine—hypothyroidism	0.00502	0.0082	CcSEcCtD
Duloxetine—Dehydration—Dextrothyroxine—hypothyroidism	0.00492	0.00805	CcSEcCtD
Duloxetine—Dehydration—Levothyroxine—hypothyroidism	0.00492	0.00805	CcSEcCtD
Duloxetine—Muscular weakness—Dextrothyroxine—hypothyroidism	0.00467	0.00763	CcSEcCtD
Duloxetine—Muscular weakness—Levothyroxine—hypothyroidism	0.00467	0.00763	CcSEcCtD
Duloxetine—Dysphagia—Dextrothyroxine—hypothyroidism	0.00458	0.00748	CcSEcCtD
Duloxetine—Dysphagia—Levothyroxine—hypothyroidism	0.00458	0.00748	CcSEcCtD
Duloxetine—Phlebitis—Liotrix—hypothyroidism	0.00452	0.00739	CcSEcCtD
Duloxetine—Sweating increased—Dextrothyroxine—hypothyroidism	0.00446	0.00728	CcSEcCtD
Duloxetine—Sweating increased—Levothyroxine—hypothyroidism	0.00446	0.00728	CcSEcCtD
Duloxetine—Disorientation—Liotrix—hypothyroidism	0.00435	0.00711	CcSEcCtD
Duloxetine—Cardiac failure congestive—Liotrix—hypothyroidism	0.00429	0.00702	CcSEcCtD
Duloxetine—Body temperature increased—Liothyronine—hypothyroidism	0.00419	0.00685	CcSEcCtD
Duloxetine—Increased appetite—Liotrix—hypothyroidism	0.00414	0.00677	CcSEcCtD
Duloxetine—Weight decreased—Levothyroxine—hypothyroidism	0.00414	0.00677	CcSEcCtD
Duloxetine—Weight decreased—Dextrothyroxine—hypothyroidism	0.00414	0.00677	CcSEcCtD
Duloxetine—Renal impairment—Liotrix—hypothyroidism	0.00409	0.00669	CcSEcCtD
Duloxetine—Acute coronary syndrome—Dextrothyroxine—hypothyroidism	0.00402	0.00657	CcSEcCtD
Duloxetine—Acute coronary syndrome—Levothyroxine—hypothyroidism	0.00402	0.00657	CcSEcCtD
Duloxetine—Myocardial infarction—Dextrothyroxine—hypothyroidism	0.004	0.00654	CcSEcCtD
Duloxetine—Myocardial infarction—Levothyroxine—hypothyroidism	0.004	0.00654	CcSEcCtD
Duloxetine—Hypoglycaemia—Liotrix—hypothyroidism	0.00399	0.00652	CcSEcCtD
Duloxetine—Cardiac failure—Liotrix—hypothyroidism	0.00399	0.00652	CcSEcCtD
Duloxetine—SLC6A4—Synaptic Vesicle Pathway—CLTC—hypothyroidism	0.00394	0.0268	CbGpPWpGaD
Duloxetine—Affect lability—Liotrix—hypothyroidism	0.00383	0.00626	CcSEcCtD
Duloxetine—Irritability—Liotrix—hypothyroidism	0.00372	0.00607	CcSEcCtD
Duloxetine—Mood swings—Liotrix—hypothyroidism	0.00369	0.00603	CcSEcCtD
Duloxetine—Blood creatinine increased—Liotrix—hypothyroidism	0.00365	0.00596	CcSEcCtD
Duloxetine—Dehydration—Liotrix—hypothyroidism	0.00362	0.00592	CcSEcCtD
Duloxetine—SLC6A2—gonad—hypothyroidism	0.00359	0.0149	CbGeAlD
Duloxetine—SLC6A4—blood—hypothyroidism	0.00355	0.0147	CbGeAlD
Duloxetine—Muscular weakness—Liotrix—hypothyroidism	0.00343	0.00561	CcSEcCtD
Duloxetine—Flushing—Levothyroxine—hypothyroidism	0.0034	0.00556	CcSEcCtD
Duloxetine—Flushing—Dextrothyroxine—hypothyroidism	0.0034	0.00556	CcSEcCtD
Duloxetine—Dysphagia—Liotrix—hypothyroidism	0.00337	0.0055	CcSEcCtD
Duloxetine—Sweating increased—Liotrix—hypothyroidism	0.00328	0.00536	CcSEcCtD
Duloxetine—Arrhythmia—Dextrothyroxine—hypothyroidism	0.00327	0.00535	CcSEcCtD
Duloxetine—Arrhythmia—Levothyroxine—hypothyroidism	0.00327	0.00535	CcSEcCtD
Duloxetine—Alopecia—Levothyroxine—hypothyroidism	0.00324	0.00529	CcSEcCtD
Duloxetine—Alopecia—Dextrothyroxine—hypothyroidism	0.00324	0.00529	CcSEcCtD
Duloxetine—SLC6A3—testis—hypothyroidism	0.0032	0.0133	CbGeAlD
Duloxetine—Tension—Levothyroxine—hypothyroidism	0.00313	0.00511	CcSEcCtD
Duloxetine—Tension—Dextrothyroxine—hypothyroidism	0.00313	0.00511	CcSEcCtD
Duloxetine—SLC6A2—adrenal gland—hypothyroidism	0.00313	0.013	CbGeAlD
Duloxetine—Nervousness—Levothyroxine—hypothyroidism	0.0031	0.00506	CcSEcCtD
Duloxetine—Nervousness—Dextrothyroxine—hypothyroidism	0.0031	0.00506	CcSEcCtD
Duloxetine—Weight decreased—Liotrix—hypothyroidism	0.00305	0.00498	CcSEcCtD
Duloxetine—NPY1R—Peptide ligand-binding receptors—TRH—hypothyroidism	0.00303	0.0207	CbGpPWpGaD
Duloxetine—Tremor—Dextrothyroxine—hypothyroidism	0.00299	0.00488	CcSEcCtD
Duloxetine—Tremor—Levothyroxine—hypothyroidism	0.00299	0.00488	CcSEcCtD
Duloxetine—SLC6A3—cerebellum—hypothyroidism	0.00296	0.0123	CbGeAlD
Duloxetine—Acute coronary syndrome—Liotrix—hypothyroidism	0.00296	0.00484	CcSEcCtD
Duloxetine—Renal failure—Liotrix—hypothyroidism	0.00295	0.00482	CcSEcCtD
Duloxetine—Myocardial infarction—Liotrix—hypothyroidism	0.00294	0.00481	CcSEcCtD
Duloxetine—Agitation—Dextrothyroxine—hypothyroidism	0.00293	0.00479	CcSEcCtD
Duloxetine—Agitation—Levothyroxine—hypothyroidism	0.00293	0.00479	CcSEcCtD
Duloxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00292	0.0199	CbGpPWpGaD
Duloxetine—Angioedema—Dextrothyroxine—hypothyroidism	0.00291	0.00476	CcSEcCtD
Duloxetine—Angioedema—Levothyroxine—hypothyroidism	0.00291	0.00476	CcSEcCtD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—DLX2—hypothyroidism	0.00285	0.0194	CbGpPWpGaD
Duloxetine—Palpitations—Levothyroxine—hypothyroidism	0.00282	0.0046	CcSEcCtD
Duloxetine—Palpitations—Dextrothyroxine—hypothyroidism	0.00282	0.0046	CcSEcCtD
Duloxetine—Convulsion—Levothyroxine—hypothyroidism	0.00276	0.00451	CcSEcCtD
Duloxetine—Convulsion—Dextrothyroxine—hypothyroidism	0.00276	0.00451	CcSEcCtD
Duloxetine—Arthralgia—Levothyroxine—hypothyroidism	0.00271	0.00444	CcSEcCtD
Duloxetine—Arthralgia—Dextrothyroxine—hypothyroidism	0.00271	0.00444	CcSEcCtD
Duloxetine—Anxiety—Levothyroxine—hypothyroidism	0.00271	0.00442	CcSEcCtD
Duloxetine—Anxiety—Dextrothyroxine—hypothyroidism	0.00271	0.00442	CcSEcCtD
Duloxetine—Hypoaesthesia—Liotrix—hypothyroidism	0.00268	0.00438	CcSEcCtD
Duloxetine—Confusional state—Levothyroxine—hypothyroidism	0.00262	0.00429	CcSEcCtD
Duloxetine—Confusional state—Dextrothyroxine—hypothyroidism	0.00262	0.00429	CcSEcCtD
Duloxetine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00259	0.0176	CbGpPWpGaD
Duloxetine—SLC6A2—testis—hypothyroidism	0.00259	0.0107	CbGeAlD
Duloxetine—Shock—Dextrothyroxine—hypothyroidism	0.00256	0.00418	CcSEcCtD
Duloxetine—Shock—Levothyroxine—hypothyroidism	0.00256	0.00418	CcSEcCtD
Duloxetine—Tachycardia—Dextrothyroxine—hypothyroidism	0.00254	0.00415	CcSEcCtD
Duloxetine—Tachycardia—Levothyroxine—hypothyroidism	0.00254	0.00415	CcSEcCtD
Duloxetine—HTR2A—heart—hypothyroidism	0.00252	0.0104	CbGeAlD
Duloxetine—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00252	0.00411	CcSEcCtD
Duloxetine—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00252	0.00411	CcSEcCtD
Duloxetine—Flushing—Liotrix—hypothyroidism	0.0025	0.00409	CcSEcCtD
Duloxetine—SLC6A4—NRF2 pathway—SLC5A7—hypothyroidism	0.00245	0.0167	CbGpPWpGaD
Duloxetine—Arrhythmia—Liotrix—hypothyroidism	0.00241	0.00393	CcSEcCtD
Duloxetine—CYP1A2—blood—hypothyroidism	0.0024	0.00996	CbGeAlD
Duloxetine—Alopecia—Liotrix—hypothyroidism	0.00238	0.00389	CcSEcCtD
Duloxetine—HTR2A—cardiovascular system—hypothyroidism	0.00238	0.00985	CbGeAlD
Duloxetine—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.00237	0.00387	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.00237	0.00387	CcSEcCtD
Duloxetine—Insomnia—Levothyroxine—hypothyroidism	0.00235	0.00385	CcSEcCtD
Duloxetine—Insomnia—Dextrothyroxine—hypothyroidism	0.00235	0.00385	CcSEcCtD
Duloxetine—CYP1A2—thyroid gland—hypothyroidism	0.00232	0.00961	CbGeAlD
Duloxetine—Flatulence—Liotrix—hypothyroidism	0.00231	0.00378	CcSEcCtD
Duloxetine—Tension—Liotrix—hypothyroidism	0.0023	0.00376	CcSEcCtD
Duloxetine—Dysgeusia—Liotrix—hypothyroidism	0.0023	0.00375	CcSEcCtD
Duloxetine—Nervousness—Liotrix—hypothyroidism	0.00228	0.00372	CcSEcCtD
Duloxetine—Fatigue—Levothyroxine—hypothyroidism	0.00224	0.00367	CcSEcCtD
Duloxetine—Fatigue—Dextrothyroxine—hypothyroidism	0.00224	0.00367	CcSEcCtD
Duloxetine—Vision blurred—Liotrix—hypothyroidism	0.00221	0.00361	CcSEcCtD
Duloxetine—Tremor—Liotrix—hypothyroidism	0.0022	0.00359	CcSEcCtD
Duloxetine—HTR2A—gonad—hypothyroidism	0.00216	0.00894	CbGeAlD
Duloxetine—Agitation—Liotrix—hypothyroidism	0.00216	0.00352	CcSEcCtD
Duloxetine—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.00214	0.0035	CcSEcCtD
Duloxetine—Feeling abnormal—Levothyroxine—hypothyroidism	0.00214	0.0035	CcSEcCtD
Duloxetine—Angioedema—Liotrix—hypothyroidism	0.00214	0.0035	CcSEcCtD
Duloxetine—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.00213	0.00348	CcSEcCtD
Duloxetine—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.00213	0.00348	CcSEcCtD
Duloxetine—SLC6A2—NRF2 pathway—SLC5A7—hypothyroidism	0.00211	0.0143	CbGpPWpGaD
Duloxetine—Syncope—Liotrix—hypothyroidism	0.0021	0.00344	CcSEcCtD
Duloxetine—HTR2A—pituitary gland—hypothyroidism	0.0021	0.00872	CbGeAlD
Duloxetine—Palpitations—Liotrix—hypothyroidism	0.00207	0.00339	CcSEcCtD
Duloxetine—Urticaria—Dextrothyroxine—hypothyroidism	0.00207	0.00338	CcSEcCtD
Duloxetine—Urticaria—Levothyroxine—hypothyroidism	0.00207	0.00338	CcSEcCtD
Duloxetine—Loss of consciousness—Liotrix—hypothyroidism	0.00206	0.00337	CcSEcCtD
Duloxetine—Abdominal pain—Levothyroxine—hypothyroidism	0.00206	0.00336	CcSEcCtD
Duloxetine—Body temperature increased—Levothyroxine—hypothyroidism	0.00206	0.00336	CcSEcCtD
Duloxetine—Abdominal pain—Dextrothyroxine—hypothyroidism	0.00206	0.00336	CcSEcCtD
Duloxetine—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00206	0.00336	CcSEcCtD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.00204	0.0139	CbGpPWpGaD
Duloxetine—Convulsion—Liotrix—hypothyroidism	0.00203	0.00332	CcSEcCtD
Duloxetine—Hypertension—Liotrix—hypothyroidism	0.00202	0.00331	CcSEcCtD
Duloxetine—Arthralgia—Liotrix—hypothyroidism	0.002	0.00326	CcSEcCtD
Duloxetine—Chest pain—Liotrix—hypothyroidism	0.002	0.00326	CcSEcCtD
Duloxetine—Anxiety—Liotrix—hypothyroidism	0.00199	0.00325	CcSEcCtD
Duloxetine—Confusional state—Liotrix—hypothyroidism	0.00193	0.00315	CcSEcCtD
Duloxetine—Oedema—Liotrix—hypothyroidism	0.00191	0.00313	CcSEcCtD
Duloxetine—Anaphylactic shock—Liotrix—hypothyroidism	0.00191	0.00313	CcSEcCtD
Duloxetine—Infection—Liotrix—hypothyroidism	0.0019	0.00311	CcSEcCtD
Duloxetine—Shock—Liotrix—hypothyroidism	0.00188	0.00308	CcSEcCtD
Duloxetine—HTR2A—adrenal gland—hypothyroidism	0.00188	0.00779	CbGeAlD
Duloxetine—CYP1A2—liver—hypothyroidism	0.00188	0.00779	CbGeAlD
Duloxetine—HTR2A—blood—hypothyroidism	0.00188	0.00779	CbGeAlD
Duloxetine—Tachycardia—Liotrix—hypothyroidism	0.00187	0.00305	CcSEcCtD
Duloxetine—SLC6A3—NRF2 pathway—SLC5A7—hypothyroidism	0.00187	0.0127	CbGpPWpGaD
Duloxetine—Asthenia—Levothyroxine—hypothyroidism	0.00187	0.00305	CcSEcCtD
Duloxetine—Asthenia—Dextrothyroxine—hypothyroidism	0.00187	0.00305	CcSEcCtD
Duloxetine—Hyperhidrosis—Liotrix—hypothyroidism	0.00185	0.00302	CcSEcCtD
Duloxetine—Pruritus—Levothyroxine—hypothyroidism	0.00184	0.00301	CcSEcCtD
Duloxetine—Pruritus—Dextrothyroxine—hypothyroidism	0.00184	0.00301	CcSEcCtD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—THRB—hypothyroidism	0.00184	0.0125	CbGpPWpGaD
Duloxetine—Anorexia—Liotrix—hypothyroidism	0.00182	0.00298	CcSEcCtD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.00181	0.0123	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.00181	0.0123	CbGpPWpGaD
Duloxetine—Diarrhoea—Levothyroxine—hypothyroidism	0.00178	0.00291	CcSEcCtD
Duloxetine—Diarrhoea—Dextrothyroxine—hypothyroidism	0.00178	0.00291	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.00174	0.00285	CcSEcCtD
Duloxetine—Insomnia—Liotrix—hypothyroidism	0.00173	0.00283	CcSEcCtD
Duloxetine—Paraesthesia—Liotrix—hypothyroidism	0.00172	0.00281	CcSEcCtD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—DLX2—hypothyroidism	0.00172	0.0117	CbGpPWpGaD
Duloxetine—CYP2D6—blood—hypothyroidism	0.00171	0.00709	CbGeAlD
Duloxetine—Decreased appetite—Liotrix—hypothyroidism	0.00166	0.00272	CcSEcCtD
Duloxetine—Vomiting—Levothyroxine—hypothyroidism	0.00165	0.0027	CcSEcCtD
Duloxetine—Vomiting—Dextrothyroxine—hypothyroidism	0.00165	0.0027	CcSEcCtD
Duloxetine—Fatigue—Liotrix—hypothyroidism	0.00165	0.0027	CcSEcCtD
Duloxetine—Rash—Levothyroxine—hypothyroidism	0.00164	0.00268	CcSEcCtD
Duloxetine—Rash—Dextrothyroxine—hypothyroidism	0.00164	0.00268	CcSEcCtD
Duloxetine—Dermatitis—Dextrothyroxine—hypothyroidism	0.00164	0.00268	CcSEcCtD
Duloxetine—Dermatitis—Levothyroxine—hypothyroidism	0.00164	0.00268	CcSEcCtD
Duloxetine—Constipation—Liotrix—hypothyroidism	0.00164	0.00268	CcSEcCtD
Duloxetine—Headache—Levothyroxine—hypothyroidism	0.00163	0.00266	CcSEcCtD
Duloxetine—Headache—Dextrothyroxine—hypothyroidism	0.00163	0.00266	CcSEcCtD
Duloxetine—CYP2D6—female gonad—hypothyroidism	0.0016	0.00662	CbGeAlD
Duloxetine—NPY1R—Peptide ligand-binding receptors—AVP—hypothyroidism	0.00159	0.0108	CbGpPWpGaD
Duloxetine—Feeling abnormal—Liotrix—hypothyroidism	0.00158	0.00258	CcSEcCtD
Duloxetine—SLC6A4—Circadian rythm related genes—NKX2-1—hypothyroidism	0.00157	0.0107	CbGpPWpGaD
Duloxetine—Gastrointestinal pain—Liotrix—hypothyroidism	0.00157	0.00256	CcSEcCtD
Duloxetine—HTR2A—testis—hypothyroidism	0.00155	0.00644	CbGeAlD
Duloxetine—NPY1R—GPCR ligand binding—TRH—hypothyroidism	0.00155	0.0105	CbGpPWpGaD
Duloxetine—Nausea—Levothyroxine—hypothyroidism	0.00155	0.00253	CcSEcCtD
Duloxetine—Nausea—Dextrothyroxine—hypothyroidism	0.00155	0.00253	CcSEcCtD
Duloxetine—Urticaria—Liotrix—hypothyroidism	0.00152	0.00249	CcSEcCtD
Duloxetine—Abdominal pain—Liotrix—hypothyroidism	0.00151	0.00247	CcSEcCtD
Duloxetine—Body temperature increased—Liotrix—hypothyroidism	0.00151	0.00247	CcSEcCtD
Duloxetine—HTR2A—liver—hypothyroidism	0.00147	0.00609	CbGeAlD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.00145	0.00988	CbGpPWpGaD
Duloxetine—HTR2A—cerebellum—hypothyroidism	0.00143	0.00595	CbGeAlD
Duloxetine—CYP2D6—testis—hypothyroidism	0.00142	0.00587	CbGeAlD
Duloxetine—Hypersensitivity—Liotrix—hypothyroidism	0.00141	0.0023	CcSEcCtD
Duloxetine—HTR6—G alpha (s) signalling events—TSHB—hypothyroidism	0.0014	0.00955	CbGpPWpGaD
Duloxetine—HTR6—G alpha (s) signalling events—TSHR—hypothyroidism	0.0014	0.00955	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—TSHB—hypothyroidism	0.00138	0.0094	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—TSHR—hypothyroidism	0.00138	0.0094	CbGpPWpGaD
Duloxetine—Asthenia—Liotrix—hypothyroidism	0.00137	0.00224	CcSEcCtD
Duloxetine—Pruritus—Liotrix—hypothyroidism	0.00135	0.00221	CcSEcCtD
Duloxetine—CYP2D6—liver—hypothyroidism	0.00134	0.00555	CbGeAlD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.00133	0.00904	CbGpPWpGaD
Duloxetine—Diarrhoea—Liotrix—hypothyroidism	0.00131	0.00214	CcSEcCtD
Duloxetine—CYP2D6—cerebellum—hypothyroidism	0.00131	0.00542	CbGeAlD
Duloxetine—Dizziness—Liotrix—hypothyroidism	0.00127	0.00207	CcSEcCtD
Duloxetine—Vomiting—Liotrix—hypothyroidism	0.00122	0.00199	CcSEcCtD
Duloxetine—Rash—Liotrix—hypothyroidism	0.00121	0.00197	CcSEcCtD
Duloxetine—Dermatitis—Liotrix—hypothyroidism	0.00121	0.00197	CcSEcCtD
Duloxetine—Headache—Liotrix—hypothyroidism	0.0012	0.00196	CcSEcCtD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.00118	0.00801	CbGpPWpGaD
Duloxetine—Nausea—Liotrix—hypothyroidism	0.00114	0.00186	CcSEcCtD
Duloxetine—SLC6A3—Neuronal System—SLC5A7—hypothyroidism	0.00111	0.00757	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—THRB—hypothyroidism	0.00111	0.00753	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.0011	0.00749	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.00107	0.00728	CbGpPWpGaD
Duloxetine—NPY1R—Peptide ligand-binding receptors—POMC—hypothyroidism	0.00106	0.00721	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—SLC5A5—hypothyroidism	0.00098	0.00667	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000975	0.00664	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000935	0.00637	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—POMC—hypothyroidism	0.000894	0.00608	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—TRH—hypothyroidism	0.000876	0.00596	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—SLC5A5—hypothyroidism	0.000842	0.00573	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—TRH—hypothyroidism	0.000835	0.00568	CbGpPWpGaD
Duloxetine—HTR6—G alpha (s) signalling events—AVP—hypothyroidism	0.000827	0.00563	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—AVP—hypothyroidism	0.000814	0.00554	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—TRH—hypothyroidism	0.000796	0.00541	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—TSHB—hypothyroidism	0.000781	0.00531	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—TSHR—hypothyroidism	0.000781	0.00531	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000751	0.00511	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.000747	0.00508	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—SLC5A5—hypothyroidism	0.000746	0.00508	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.000732	0.00498	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—TRH—hypothyroidism	0.000725	0.00493	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—NEFL—hypothyroidism	0.000717	0.00488	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000711	0.00484	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—TSHR—hypothyroidism	0.000709	0.00482	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—TSHB—hypothyroidism	0.000709	0.00482	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000675	0.00459	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000669	0.00455	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000669	0.00455	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.000648	0.00441	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000598	0.00407	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—AVP—hypothyroidism	0.000597	0.00406	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—TRH—hypothyroidism	0.000572	0.00389	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000559	0.00381	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000553	0.00376	CbGpPWpGaD
Duloxetine—HTR6—G alpha (s) signalling events—POMC—hypothyroidism	0.00055	0.00374	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CLTC—hypothyroidism	0.000544	0.0037	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—POMC—hypothyroidism	0.000541	0.00368	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000531	0.00361	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—TSHB—hypothyroidism	0.00051	0.00347	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—TSHR—hypothyroidism	0.00051	0.00347	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000496	0.00337	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000493	0.00335	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000493	0.00335	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.00048	0.00327	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—VAV3—hypothyroidism	0.000478	0.00325	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.00047	0.0032	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TRH—hypothyroidism	0.00047	0.0032	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—AVP—hypothyroidism	0.00046	0.00313	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.00044	0.003	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—AVP—hypothyroidism	0.000439	0.00298	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—VAV3—hypothyroidism	0.000434	0.00295	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000428	0.00291	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000428	0.00291	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—TRH—hypothyroidism	0.000421	0.00287	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TSHB—hypothyroidism	0.000419	0.00285	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TSHR—hypothyroidism	0.000419	0.00285	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000418	0.00284	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AVP—hypothyroidism	0.000418	0.00284	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000394	0.00268	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000392	0.00267	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—AVP—hypothyroidism	0.000381	0.00259	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—TSHB—hypothyroidism	0.000375	0.00255	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—TSHR—hypothyroidism	0.000375	0.00255	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SH2B3—hypothyroidism	0.000373	0.00254	CbGpPWpGaD
Duloxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000373	0.00254	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.00037	0.00252	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—TRH—hypothyroidism	0.000366	0.00249	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000341	0.00232	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—TSHB—hypothyroidism	0.000326	0.00222	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—TSHR—hypothyroidism	0.000326	0.00222	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—TRH—hypothyroidism	0.000323	0.0022	CbGpPWpGaD
Duloxetine—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000316	0.00215	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—POMC—hypothyroidism	0.000306	0.00208	CbGpPWpGaD
Duloxetine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000302	0.00206	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—AVP—hypothyroidism	0.0003	0.00204	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TRH—hypothyroidism	0.000293	0.002	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.00029	0.00198	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—TSHR—hypothyroidism	0.000288	0.00196	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—TSHB—hypothyroidism	0.000288	0.00196	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—POMC—hypothyroidism	0.000278	0.00189	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PRL—hypothyroidism	0.000277	0.00188	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.00027	0.00184	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000262	0.00178	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TSHR—hypothyroidism	0.000262	0.00178	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TSHB—hypothyroidism	0.000262	0.00178	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VAV3—hypothyroidism	0.000256	0.00174	CbGpPWpGaD
Duloxetine—CYP1A2—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000256	0.00174	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000252	0.00172	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AVP—hypothyroidism	0.000247	0.00168	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000239	0.00163	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TRH—hypothyroidism	0.000238	0.00162	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—AVP—hypothyroidism	0.000221	0.00151	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TRH—hypothyroidism	0.000216	0.00147	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000212	0.00145	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TSHB—hypothyroidism	0.000212	0.00144	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TSHR—hypothyroidism	0.000212	0.00144	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TRH—hypothyroidism	0.000207	0.00141	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CLTC—hypothyroidism	0.000201	0.00136	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—POMC—hypothyroidism	0.0002	0.00136	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000193	0.00131	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TSHB—hypothyroidism	0.000193	0.00131	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TSHR—hypothyroidism	0.000193	0.00131	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—AVP—hypothyroidism	0.000192	0.00131	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—IYD—hypothyroidism	0.000189	0.00129	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000188	0.00128	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TRH—hypothyroidism	0.000188	0.00128	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TSHB—hypothyroidism	0.000184	0.00125	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TSHR—hypothyroidism	0.000184	0.00125	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—VAV3—hypothyroidism	0.000176	0.0012	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TRH—hypothyroidism	0.000173	0.00118	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AVP—hypothyroidism	0.00017	0.00116	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000168	0.00114	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TSHB—hypothyroidism	0.000167	0.00114	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TSHR—hypothyroidism	0.000167	0.00114	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—POMC—hypothyroidism	0.000164	0.00112	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ATP5O—hypothyroidism	0.000161	0.0011	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—POMC—hypothyroidism	0.00016	0.00109	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—IYD—hypothyroidism	0.00016	0.00109	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—VAV3—hypothyroidism	0.00016	0.00109	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IGF1—hypothyroidism	0.000158	0.00107	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TSHB—hypothyroidism	0.000155	0.00105	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TSHR—hypothyroidism	0.000155	0.00105	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AVP—hypothyroidism	0.000154	0.00105	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TPO—hypothyroidism	0.000151	0.00103	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CLTC—hypothyroidism	0.000148	0.00101	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—POMC—hypothyroidism	0.000147	0.001	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SH2B3—hypothyroidism	0.000138	0.000937	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ATP5O—hypothyroidism	0.000136	0.000928	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—POMC—hypothyroidism	0.000136	0.000925	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—VAV3—hypothyroidism	0.00013	0.000883	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CLTC—hypothyroidism	0.000128	0.000873	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TPO—hypothyroidism	0.000128	0.000872	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TRH—hypothyroidism	0.000128	0.000869	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—POMC—hypothyroidism	0.000128	0.000869	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AVP—hypothyroidism	0.000125	0.000851	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000119	0.000808	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—VAV3—hypothyroidism	0.000118	0.000802	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TSHB—hypothyroidism	0.000114	0.000774	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TSHR—hypothyroidism	0.000114	0.000774	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AVP—hypothyroidism	0.000114	0.000772	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—POMC—hypothyroidism	0.000113	0.000768	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—VAV3—hypothyroidism	0.000113	0.000767	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TRH—hypothyroidism	0.000111	0.000754	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AVP—hypothyroidism	0.000109	0.000739	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—POMC—hypothyroidism	0.000102	0.000697	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—VAV3—hypothyroidism	0.000102	0.000696	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PRL—hypothyroidism	0.000102	0.000695	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SH2B3—hypothyroidism	0.000101	0.00069	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TSHB—hypothyroidism	9.88e-05	0.000672	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TSHR—hypothyroidism	9.88e-05	0.000672	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AVP—hypothyroidism	9.86e-05	0.000671	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VAV3—hypothyroidism	9.45e-05	0.000643	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AVP—hypothyroidism	9.11e-05	0.00062	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SH2B3—hypothyroidism	8.81e-05	0.000599	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—POMC—hypothyroidism	8.31e-05	0.000565	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—POMC—hypothyroidism	7.54e-05	0.000513	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRL—hypothyroidism	7.52e-05	0.000512	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—POMC—hypothyroidism	7.21e-05	0.000491	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TSHB—hypothyroidism	7.01e-05	0.000477	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VAV3—hypothyroidism	6.96e-05	0.000474	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AVP—hypothyroidism	6.71e-05	0.000456	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—POMC—hypothyroidism	6.55e-05	0.000446	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRL—hypothyroidism	6.53e-05	0.000445	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	6.24e-05	0.000425	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—POMC—hypothyroidism	6.05e-05	0.000412	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VAV3—hypothyroidism	6.04e-05	0.000411	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TSHB—hypothyroidism	5.93e-05	0.000404	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AVP—hypothyroidism	5.82e-05	0.000396	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1—hypothyroidism	5.82e-05	0.000396	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3C2A—hypothyroidism	5.29e-05	0.00036	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC5A5—hypothyroidism	5.24e-05	0.000357	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	5.22e-05	0.000355	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—POMC—hypothyroidism	4.46e-05	0.000303	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC5A5—hypothyroidism	4.44e-05	0.000302	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—hypothyroidism	4.29e-05	0.000292	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—POMC—hypothyroidism	3.87e-05	0.000263	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—hypothyroidism	3.72e-05	0.000253	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—POMC—hypothyroidism	2.74e-05	0.000187	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—POMC—hypothyroidism	2.32e-05	0.000158	CbGpPWpGaD
